Camp chemotherapy for metastatic non‐oat cell bronchogenic carcinoma. A 7‐year experience (1975–1981) with 160 patients

Kirk V. Shepard, Harvey M. Golomb, Jacob D. Bitran, Philip C. Hoffman, Steven B. Newman, Tom R. Demeester, Consuelo Skosey

Research output: Contribution to journalArticle

11 Scopus citations


Between January 1975 and December 1981, 160 patients with metastatic non-oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, doxorubicin, methotrexate, and procarbazine (CAMP), or with a CAMP-like regimen. Forty-two (26%) of these patients demonstrated an objective response to the chemotherapy with a median survival of 61 weeks. Thirty-nine (24%) patients had stable disease (SD) with a median survival of 45 weeks. Seventy-nine patients (49.4%) were nonresponders with a median survival of 15 weeks. There was a significant difference in survival times between the responders and the SD patients, and between the responders and SD patients and the nonresponders. Responses were seen in 11% of the patients with squamous cell carcinoma and in 37% of the patients with adenocarcinoma. There was a significant difference in the response and SD categories in favor of adenocarcinoma over squamous cell carcinoma. Once a response was achieved, the median survival of the patients with adenocarcinoma was not significantly longer than that of the patients with squamous cell carcinoma.

Original languageEnglish (US)
Pages (from-to)2385-2390
Number of pages6
Issue number10
StatePublished - Nov 15 1985


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this